Positive Functional Modulator

Rectify Advances RTY-406 as Potential Disease-Modifying Therapy for PSC

Boston, Mass. – August 27, 2026 Rectify Pharmaceuticals presented the discovery and characterization of RTY-406, an oral, once-daily investigational...

By cGxPwire Editor
August 29, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Positive Functional Modulator

Rectify Advances RTY-406 as Potential Disease-Modifying Therapy for PSC